...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the...

9

Transcript of ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the...

Page 1: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during
Page 2: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during
Page 3: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during
Page 4: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during
Page 5: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during
Page 6: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during
Page 7: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during

(b) (4)

Page 8: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during
Page 9: ...Censored CWX= [2866,5839) - CMAX= [5839,m61] Censored [5839, Fatigue: Of the 80 patients in the PK/PD safety analyses, 45 patients (56%) had at least I occurrence of fatigue during

31 Page(s) Withheld   

______  Trade Secret / Confidential (b4)  

_x___  Draft Labeling (b4)  

______  Draft Labeling (b5)  

______  Deliberative Process (b5)